Johns Hopkins Medicine investigators say their research indicates a new combination of drugs is needed to find an effective treatment for TB meningitis due to multidrug-resistant (MDR) strains
NIH’s National Institute of Allergy and Infectious Diseases awarded Texas Biomedical Research Institute and The Access to Advanced Health Institute in Seattle, Washington, a $3.5 million, five-year Innovation for Tuberculosis Vaccine Discovery grant.
Focus of the work is bolstering B-cell immunity to help body beat bacteria
The compound TA-C is metabolized by TB bacteria – weakening the germ from within like a ‘Trojan horse’ attack
From studies in her lab at Stony Brook University in New York to private-sector collaborations, Hertz Fellow Jessica Seeliger is accelerating the fight against multiple deadly diseases.
In support of World TB Day, March 24, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, joins the World Health Organization campaign urging governments to act on the commitments made to end TB.
Most delays ranged between 10 and 45 days, with a median of 24 days, after a visit to a doctor, which exceeds current World Health Organization recommendations of diagnosing and treating TB within two to three weeks of symptom onset
Delays were linked to greater risk for disease complications, transmission of infection to household members
Older individuals and those with compromised immunity were at greater risk for delayed diagnoses
Use of diagnostic molecular testing, use of chest imaging and being seen by a specialist were all linked to more prompt identification of TB infection, suggesting delays may be preventable
Findings underscore the need to increase awareness of TB among frontline clinicians who may not suspect TB due to rarity of infection in this country
This World AIDS Day, the Forum of International Respiratory Societies (FIRS), of which the ATS is a founding member, is calling on governments, health advocates and non-government organizations to strengthen their response to AIDS and tuberculosis, and to ensure that TB services are maintained throughout their response to COVID-19.
Rutgers researchers have been awarded a $20 million grant by the National Institutes of Health (NIH) to evaluate new point of care tests that would diagnose Tuberculosis, the number one cause of deaths worldwide due to an infectious disease.
Within a month following a heart attack, people are at increased risk for a second one. As a result, physicians treat these patients with medications to rapidly reduce cardiovascular risk factors for another event. Although statins are designed to reduce the risk from one underlying problem, low-density lipoprotein (LDL) or “bad” cholesterol, they often aren’t able drop it to recommended levels within 30 days. Now, testing a next-generation cholesterol-lowering drug known as a PCSK9 inhibitor, Johns Hopkins Medicine researchers showed they could lower blood cholesterol to safer levels faster when it is added to traditional therapies.
In support of World TB Day, 24 March, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, urges governments to promote tuberculosis prevention as a critical component of TB elimination.
A new study led by Washington University School of Medicine in St. Louis offers a genetic road map detailing the similarities and differences in immune responses to TB across three species — mice, macaques and humans. According to the researchers, the insight into the immune pathways that are activated in diverse models of TB infection will serve as a valuable tool for scientists studying and working to eradicate the disease.
Worldwide, more people die from tuberculosis than any other infectious disease, even though the vast majority were vaccinated. The vaccine just isn’t that reliable. But a new Nature study finds that simply changing the way the vaccine is administered could dramatically boost its protective power.
The World Health Organization has set a goal of ending the AIDS epidemic by 2030.
The San Antonio Medical Foundation (SAMF) has awarded Texas Biomedical Research Institute Professor Jordi B. Torrelles, Ph.D., with a $173,000 grant to study a modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine shown to have promise for treating bladder cancer. BCG is a weakened strain of Mycobacterium bovis, a vaccine for tuberculosis.
A new analysis challenges the longstanding notion that tuberculous infection is a life-long infection that could strike at any time and cause tuberculosis
Following today’s release of the World Health Organization’s Global Tuberculosis Report 2019, the American Thoracic Society joins the WHO in calling for redoubled efforts to end the global TB pandemic by 2030, the goal set by the global community in the United Nations Political Declaration to End Tuberculosis on Sept. 26, 2018.
– Old lungs are not as capable as young lungs of fighting off an infection of the bacteria that causes tuberculosis (TB), placing seniors at a greater risk of developing TB. The microbe that causes this infectious disease, Mycobacterium tuberculosis (Mtb), currently kills more people in the world than any other pathogen. Texas Biomed researchers published an article in the Journal of Infectious Diseases in July 2019. The study details an experiment that took place in vitro (in the lab) and in vivo (in animals) that showed fluid in the lining of the lungs plays a big role in the elderly’s susceptibility to infection with the bacterium Mtb.
The University of Illinois at Chicago will work with TB Alliance to help find new drug treatments for tuberculosis, a bacterial infection considered to be one of the leading causes of death worldwide. TB Alliance is a nonprofit organization dedicated…